Lazertinib - Moligand™, ≥98% , Epidermal growth factor receptor erbB1 inhibitor, CAS No.1903008-80-9, Epidermal growth factor receptor erbB1 inhibitor

CAS: 1903008-80-9 Cat. No.: L414136 Formule: C30H34N8O3 Poids moléculaire: 554.64 Numéro CE: 841-500-6
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. ≥98%
Synonyms
Leclaza|(E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid|Lazertinib (YH25448)|N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide|Lazertinib [USAN:INN]|Lazertinib [INN]|2-Propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-|2beta-Carbomethoxy-3beta-benzoxytropane|Lazertinib (YH25448,GNS-1480)|(2S,3R,4S,5R,6S)-3,4,5,6-Tetrahydroxytetrahydro-2H-pyran-2-carboxylicacid|Lazertinib|YH-25448; YH 25448; YH25448; GNS-1480; GNS 1480; GNS1480|N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide|LAZERTINIB [WHO-DD]|rel-(3R,5S,E)-7-(4-(4-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl)-3,5-dihydroxyhept-6-enoicacid|GNS-1480|LAZERTINIB [INN]|N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide|N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide|YH-25448|DL-1,4-Dimercapto-2,3-dihydroxybutane
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
Taille
Allemagne (EU)
USA*
Prix
Qté
1mg
L414136-1mg
—
2 En stock

21,61€

32,89€
Enregistrer 11,28 € (34.30%)
5mg
L414136-5mg
—
2 En stock

45,90€

69,33€
Enregistrer 23,43 € (33.79%)
10mg
L414136-10mg
—
3 En stock

67,60€

101,44€
Enregistrer 33,84 € (33.36%)
25mg
L414136-25mg
—
2 En stock

116,19€

174,33€
Enregistrer 58,14 € (33.35%)
50mg
L414136-50mg
—
2 En stock

192,55€

288,87€
Enregistrer 96,32 € (33.34%)
100mg
L414136-100mg
—
2 En stock

328,79€

493,66€
Enregistrer 164,87 € (33.40%)
Enter a quantity for the sizes you want to add.

Vue d’ensemble

Information

Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversibleEGFR-TKIwith IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively, showing much higher IC50 values aganist ErbB2 and ErbB4.


Targets

Del19/T790M (Cell-free assay); L858R/T790M EGFR (Cell-free assay); Del19 (Cell-free assay); L85R (Cell-free assay); WT EGFR (Cell-free assay) 1.7 nM; 2 nM; 5 nM; 20.6 nM; 76 nM


In vitro

Lazertinib targets the activating EGFR mutations Del19 and L858R, as well as the T790M mutation, while sparing wild type. In NSCLC cell lines and primary cancer cells from patients harboring EGFR mutations, YH25448 more potently inhibits cancer cell growth and significantly increases tumor cell apoptosis compared to osimertinib. In the cell proliferation assays, GI50 values of lazertinib are 6 nM, 5 nM, and 711 nM for H1975 cells (L858R/T790M), PC9 cells (del19) and H2073 cells (wt), respectively.


In vivo

In an in vivo mouse model implanted with H1975 cells, once-daily YH25448 treatment results in indramatic dose-dependent tumor regression in both subcutaneous and intracranial lesions with no abnormal signs such as skin keratosis. The plasma half-life of YH25448 is 5.9-6.8 hr, while the tumor to plasma AUC0-last ratio is 3.0-5.1 in tumor-bearing mice. YH25448 shows excellent penetration of the blood-brain bartier, achieving CSF concentrations exceeding the IC50 value for pEGFR inhibition. YH25448 shows superior efficacy for tumor regression in an EGFR mutant brain metastasis model.


Cell Research(from reference)

Cell lines:Ba/F3 cells 

Concentrations:5, 10, 100 nM 

Incubation Time:6 h 

Spécifications

Synonymes
Leclaza | (E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid | Lazertinib (YH25448) | N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide | Lazertinib [USAN:INN] | Lazertinib [INN] | 2-Propenamide, N-(5-((4-(4-((dimethyla Afficher plus
Spécifications et pureté
Moligand™, ≥98%
Mécanismes biochimiques et physiologiques
Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively, showing much higher IC50 values aganist ErbB2 and ErbB4.
Conditions de stockage de stockage
Store at -20°C
Expédié en
Ice chest + Ice pads
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Grade
Moligand™
Type d'action
INHIBITOR
Mécanisme d'action
Epidermal growth factor receptor erbB1 inhibitor
Pureté
≥98%
Propriétés du produit
ALogP
4.56
hba_count
6
Nombre de HBD
2
Liaison rotative
10
Noms et identifiants
Pubchem Sid
Pubchem Sid Url
https://pubchem.ncbi.nlm.nih.gov/substance/504772938
SMILES
CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC
IUPAC Name
N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide
InChIKey
RRMJMHOQSALEJJ-UHFFFAOYSA-N
InChI
1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)
Isomères SMILES
CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC
Poids moléculaire
554.64
Reaxys
29384987
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=29384987&ln=

Données avancées

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassOrganoheterocyclic compounds
ClasseOxazinanes
SubclassMorpholines
Intermediate Tree Nodes Not available
Direct ParentPhenylmorpholines
Alternative Parents Phenylpyrazoles  2'-Aminoanilides  Methoxyanilines  Aminophenyl ethers  Phenoxy compounds  N-arylamides  Methoxybenzenes  Dialkylarylamines  Anisoles  Aralkylamines  Aminopyrimidines and derivatives  Alkyl aryl ethers  Heteroaromatic compounds  Acrylic acids and derivatives  Trialkylamines  Secondary carboxylic acid amides  Amino acids and derivatives  Secondary amines  Oxacyclic compounds  Dialkyl ethers  Azacyclic compounds  Organopnictogen compounds  Organic oxides  Hydrocarbon derivatives  Carbonyl compounds  
Molecular FrameworkAromatic heteromonocyclic compounds
Substituents Phenylmorpholine - Phenylpyrazole - 2'-aminoanilide - Aminophenyl ether - Methoxyaniline - Anilide - Phenoxy compound - Methoxybenzene - Aniline or substituted anilines - Dialkylarylamine - N-arylamide - Tertiary aliphatic/aromatic amine - Phenol ether - Anisole - Aralkylamine - Aminopyrimidine - Alkyl aryl ether - Benzenoid - Pyrimidine - Monocyclic benzene moiety - Acrylic acid or derivatives - Heteroaromatic compound - Pyrazole - Azole - Tertiary aliphatic amine - Tertiary amine - Secondary carboxylic acid amide - Carboxamide group - Amino acid or derivatives - Oxacycle - Azacycle - Secondary amine - Ether - Dialkyl ether - Carboxylic acid derivative - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Carbonyl group - Amine - Aromatic heteromonocyclic compound
DescriptionThis compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
External Descriptors Not available
Structure 3D
Modèle de structure chimique interactif





Cibles associées (humaines)
EGFR Tclin Epidermal growth factor receptor (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
JAK3 Tclin Tyrosine-protein kinase JAK3 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SYK Tclin Tyrosine-protein kinase SYK (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
KDR Tclin Vascular endothelial growth factor receptor 2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H1975 (4994 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
U2OS (164939 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
U-87 MG (3946 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A-431 (6446 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEK-293T (167025 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cibles associées (non humaines)
BaF3 (4657 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mécanismes d'action
Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

9 results found

Lot NumberCertificate TypeDateArticle
K2221059K2221059Certificate of AnalysisSep 04, 2025 L414136
K2221069K2221069Certificate of AnalysisSep 04, 2025 L414136
K2221070K2221070Certificate of AnalysisSep 04, 2025 L414136
K2221072K2221072Certificate of AnalysisSep 04, 2025 L414136
K2221088K2221088Certificate of AnalysisSep 04, 2025 L414136
K2221090K2221090Certificate of AnalysisSep 04, 2025 L414136
H2514127H2514127Certificate of AnalysisSep 20, 2022 L414136
L2417142L2417142Certificate of AnalysisSep 20, 2022 L414136
L2420380L2420380Certificate of AnalysisSep 20, 2022 L414136
Propriétés chimiques et physiques
SolubilitéSolubility (25°C) In vitro DMSO: 4 mg/mL (7.21 mM); Water: Insoluble; Ethanol: Insoluble;
DMSO (mg/mL) Solubilité maximale4
DMSO (mM) Solubilité maximale7.21184929917773
Eau (mg/mL) Solubilité maximale<1
Poids moléculaire554.6
XLogP33.400
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count10
Exact Mass554.275 Da
Monoisotopic Mass554.275 Da
Topological Polar Surface Area110.000 Ų
Heavy Atom Count41
Formal Charge0
Complexity837.000
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
Sécurité et dangers (GHS)
Pictogramme(s)
GHS07,   GHS08
Signal
Danger
Mentions de danger

H302:Harmful if swallowed

H317:May cause an allergic skin reaction

H361:Suspected of damaging fertility or the unborn child

H372:Causes damage to organs through prolonged or repeated exposure

Conseils de prudence

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P264:Wash hands [and …] thoroughly after handling.

P270:Do not eat, drink or smoke when using this product.

P272:Contaminated work clothing should not be allowed out of the workplace.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P321:Specific treatment (see ... on this label).

P330:Rinse mouth.

P302+P352:IF ON SKIN: wash with plenty of water.

P333+P313:IF SKIN irritation or rash occurs: Get medical advice/attention.

P362+P364:Take off contaminated clothing and wash it before reuse.

P405:Store locked up.

P501:Dispose of contents/container to an approved waste disposal plant.

P203:Obtain, read and follow all safety instructions before use.

P301+P317:IF SWALLOWED: Get medical help.

P318:if exposed or concerned, get medical advice.

P319:Get medical help if you feel unwell.

Reaxys
29384987
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=29384987&ln=
Calculateurs de solution
Avis

Avis des clients

Application Protocols

Validated application protocols (e.g., specific assay formats, concentrations, or cell models) are not provided in the Product Data for this SKU.

General guidance for small-molecule tool compounds:

  • Stock solutions: Prepare 10–50 mM in anhydrous DMSO. Store aliquots at −20 °C. Thaw once and avoid repeated freeze–thaw.
  • Dose–response assays: Begin with serial dilutions (e.g., 10-point, 3-fold) to cover nM–μM ranges appropriate for covalent kinase inhibitors; maintain final DMSO ≤0.1–0.5%.
  • Controls: Include vehicle (DMSO) controls, positive control inhibitors (class-relevant), and, where applicable, inactive analogs.
  • Readouts: For biochemical assays, use ATP-competition formats and time-dependent inhibition protocols; for cellular assays, confirm target pathway modulation with orthogonal biomarkers.

These suggestions are general, literature-informed practices and are not validated for this specific lot or item.

Biological Roles

This product is a research-use small molecule often employed as a biochemical tool compound in kinase-focused studies. Item-specific biological data are not provided; the context below is based on general literature about this scaffold class and should not be construed as a specification or clinical claim.

  • Lazertinib belongs to the class of ATP-competitive, covalent EGFR kinase inhibitors designed to target mutant EGFR in a research setting. Such scaffolds commonly feature an electrophilic acrylamide for covalent capture of a catalytic cysteine in the kinase active site.
  • Typical research applications include cell-free kinase assays, cellular pathway interrogation, target engagement studies (e.g., CETSA, activity-based protein profiling), and comparative SAR benchmarking across EGFR-family inhibitors.
  • In biochemical assay design, attention is paid to time-dependent inhibition kinetics (k_inact/K_I) characteristic of covalent inhibitors. Assay conditions (pre-incubation time, temperature, and nucleophile content in buffers) can influence apparent potency.
  • Off-target profiling in panels (e.g., kinome scans) is frequently performed to contextualize selectivity; results are compound- and lot-independent experimental outcomes and are not specified for this item.

Important: No therapeutic, diagnostic, or clinical uses are claimed or supported. Use solely as a research tool under appropriate institutional oversight.

Buffer Applications

Lazertinib is not a buffering reagent. It does not form conventional laboratory buffer systems.

Practical notes for assay buffers (general, for small-molecule bioassays):

  • Prepare compound stocks in DMSO, then dilute into assay buffers (e.g., HEPES, Tris, or PBS-based) keeping final DMSO ≤0.1–0.5% v/v to minimize biological interference.
  • Include carrier proteins (e.g., 0.1% BSA) or low levels of nonionic surfactant (e.g., 0.01–0.05% Tween-20/80) to reduce nonspecific binding and precipitation where appropriate.
  • Filter buffers (0.22 μm) and pre-warm to ambient/37°C before adding compound to avoid microprecipitation.

For experiments requiring sustained exposure, confirm stability in the chosen buffer over time (bench-top and 37°C), and assess adsorption to plastics versus glassware.

Green Alternatives

As a bioactive screening compound, Lazertinib itself is not replaceable by a “green” alternative without altering biological activity. However, greener practices can be applied to its handling and analytics.

Greener solvent and workflow choices (general guidance):

  • Prefer DMSO over DMF/NMP for stock solutions when feasible due to better toxicological and environmental profiles and lower vapor pressure.
  • For chromatography, use acetonitrile/water or ethanol/water mobile phases; minimize halogenated solvents. Optimize gradients to reduce solvent consumption.
  • Explore microscale assays and miniaturized LC (e.g., UHPLC with narrower columns) to reduce solvent volumes and waste.
  • Implement closed-vial handling and pre-diluted dosing plates to limit exposure and evaporative losses.

Illustrative comparison (general, non-item-specific):

  • DMF/NMP: strong solvency; higher toxicity; difficult waste streams.
  • DMSO: strong solvency; broadly accepted in bioassays; easier EHS profile.
  • Ethanol/PEG400 co-solvent systems: greener but may limit achievable concentrations and require careful assay compatibility checks.

Note: Any solvent change must ensure compound integrity and assay performance; confirm by stability screening and recovery checks.

Pharmaceutical Uses

No pharmaceutical or therapeutic claims are made for this product. It is provided strictly for research use only.

Relevant research-oriented, non-clinical uses:

  • Reference standard in analytical method development and validation (e.g., LC–MS system suitability, stability-indicating methods) within discovery or preclinical research laboratories.
  • In vitro DMPK studies such as solubility screening, microsomal stability, permeability assays (e.g., PAMPA/Caco-2), and protein binding, where permitted by institutional scope.
  • Formulation research (non-clinical): Pre-formulation solvent/co-solvent screening, solid-form investigations (salt/polymorph screening) to understand material behavior.

Regulatory/compendial status:

  • No pharmacopeial monograph is cited in the Product Data for this item. Any use in regulated contexts requires independent qualification and documentation (CoA, stability data, impurity profile) by the end user.
Physical Properties

Item-specific physicochemical specifications have not been provided in the Product Data and should be confirmed on the CoA/Spec Sheet for this SKU.

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point (mp): Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point (bp): Not applicable for a nonvolatile solid; specific value not specified for this item.
  • Density: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Item-specific solubility is not specified. In practice, small-molecule kinase inhibitors are commonly prepared as concentrated stocks in anhydrous DMSO (literature practice). Aqueous solubility typically increases with co-solvents (DMSO, ethanol) and surfactants (e.g., Tween-80) in biological assay buffers.
  • LogP / cLogP: Not specified for this item; refer to CoA/Spec Sheet (literature values vary by tautomer/protonation model and should not be used as specifications).
  • pKa: Not specified for this item; refer to CoA/Spec Sheet.
  • UV-Vis: Not specified for this item; refer to CoA/Spec Sheet.
  • Refractive index: Not applicable to solids; not specified for this item.

Practical notes (general, literature-informed):

  • Many EGFR inhibitors exhibit moderate-to-high lipophilicity and limited aqueous solubility at neutral pH. For analytical HPLC/LC–MS, typical eluents include acetonitrile/water with 0.1% formic acid; detection by UV (250–320 nm) is common due to aromatic chromophores. These are general observations and not item specifications.
Quality and Grades
  • Grade/Purity: Moligand™ (Aladdin small-molecule/compound library grade). This designation indicates suitability for research screening, probe development, and analytical/biochemical assay work. Exact purity specifications, impurity profiles, and acceptance criteria are item-specific and should be verified on the CoA/Spec Sheet.

What Moligand™ typically implies (general quality principles):

  • High chemical purity appropriate for biological screening and SAR studies (typical analytical controls include HPLC/UPLC purity and MS confirmation). Specific numeric thresholds are not provided here and must not be inferred.
  • Identity confirmation by orthogonal methods (e.g., LC–MS/HRMS, and/or NMR). Item-specific test methods and results are reported on the CoA.
  • Batch traceability, controlled storage, and cold-chain shipment to preserve integrity.

Stabilizers/additives:

  • None are specified in the Product Data. If stabilizers or salt forms are present, they will be listed on the CoA/Spec Sheet.

Documentation and verification:

  • For regulated or GLP-adjacent research, request the lot-specific CoA, analytical chromatograms, and any available spectral data to confirm fit-for-purpose (e.g., purity in the detector wavelength range used by your bioassay or analytics).
Reaction and Applications

This product is supplied as a finished, bioactive small molecule for research screening and assay development. It is not typically employed as a reagent or building block in synthetic transformations.

  • Not a general-purpose reagent for stoichiometric or catalytic organic reactions.
  • If synthetic modification or conjugation is intended (e.g., to prepare probes), consult the primary literature for derivatization strategies specific to the Lazertinib scaffold and confirm compatibility with your IP/licensing framework.

For laboratories performing analytical method development:

  • Applications include serving as a reference compound for LC–MS method qualification, stability-indicating assays, and matrix spiking studies (bioanalytical research context).

No named synthetic reactions or catalyst systems are typically associated with using Lazertinib as a reagent.

Reaction Conditions

Not applicable. Lazertinib is not provided as a reagent for performing chemical reactions, and no item-specific reaction conditions are relevant.

Analytical and handling conditions (general, for context):

  • Stock preparation: Dissolve in anhydrous DMSO to 10–50 mM; vortex and, if needed, sonicate briefly. Filter (0.22 μm PTFE) for sterility/clarity if required by the assay.
  • Stability checks: Evaluate solution stability at room temperature and 4 °C over 24–72 h; protect from light. Avoid prolonged exposure to strong bases/nucleophiles that can react with acrylamide motifs (general observation for covalent inhibitors).
  • Chromatography: Reverse-phase LC using C18 columns, water/acetonitrile with 0.1% formic acid, UV detection around 250–320 nm (general practice; optimize empirically).

These are general laboratory practices and do not constitute specifications for this item.

Safety and Handling

Safety classification is not specified in the Product Data. Always consult the SDS for authoritative information before use.

  • GHS Classification / Signal Word / Pictograms / H-Statements: Not specified for this item; refer to SDS.
  • General hazards (typical for bioactive small molecules; literature/precautionary): May be harmful if swallowed, inhaled, or absorbed through skin; may cause irritation to eyes, skin, and respiratory tract. Avoid generating dust or aerosols.
  • PPE: Laboratory coat, safety glasses or splash goggles, and appropriate chemical-resistant gloves (e.g., nitrile). Handle in a fume hood to minimize inhalation exposure.
  • Handling: Avoid direct contact. Use tools for weighing. Prepare solutions in a ventilated hood. For sterile work, filter stock solutions (0.22 μm) after dissolution if compatible.
  • Incompatibilities: Strong oxidizing agents and strong acids/bases may degrade typical aryl–amide/acrylamide motifs (general guidance). Avoid prolonged exposure to light and elevated temperatures.
  • First-aid (overview; defer to SDS):
    • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
    • Skin contact: Wash with soap and water; remove contaminated clothing.
    • Eye contact: Rinse cautiously with water for several minutes; seek medical attention if irritation continues.
    • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
  • Waste: Dispose of in accordance with institutional and local regulations for hazardous organic chemical waste.

Note: This product is for research use only.

Solvent Selection

Lazertinib is supplied for research screening; item-specific solubility is not provided. The following guidance reflects common practice for hydrophobic kinase inhibitors (general, literature-informed):

  • Primary stock solvent: Anhydrous DMSO is the default choice for making concentrated stocks (e.g., 10–50 mM), owing to its strong solvating ability for polyaromatic amide/heteroaryl scaffolds.
  • Alternative organic solvents: DMF, NMP, or ethanol can sometimes dissolve similar scaffolds, but DMSO generally offers superior solubility and assay compatibility at ≤0.1–0.5% v/v in final wells.
  • Aqueous buffers: Direct dissolution in water or PBS is often poor. Dilute DMSO stocks into pre-warmed buffer with vigorous mixing. Consider co-solvents (≤5% v/v ethanol or PEG400) or surfactants (e.g., 0.01–0.1% Tween-80) to mitigate precipitation at higher final concentrations.
  • Analytical solvents: For LC–MS/HPLC, mobile phases of acetonitrile/water (0.1% formic acid) are commonly used for basic/neutral analytes. Methanol may be acceptable depending on retention and peak shape.

Small comparison (general):

  • DMSO: highest solvency; widely assay-compatible at low %; can affect cells/enzymes at high %.
  • DMF/NMP: strong solvency; higher toxicity; less favored in bioassays but useful for sample prep.
  • Ethanol: greener; less solvating for highly lipophilic solids; volatility can complicate dosing.

Always verify absence of precipitation after dilution; if needed, sonicate briefly and use microfilters before dosing.

Storage and Reconstitution
  • Storage conditions (item-specific): Store at −20 °C (as provided in Product Data). Protect from light and moisture. Maintain container tightly closed.
  • Shipping (item-specific): Shipped in ice chest with ice pads to preserve integrity during transit.
  • Reconstitution:
    • Use anhydrous DMSO to prepare concentrated stock solutions (e.g., 10–50 mM). Item-specific solubility is not specified; determine empirically.
    • Vortex thoroughly; brief sonication can assist dissolution. If particulates persist, warm gently (≤37 °C) and/or filter through a 0.22 μm PTFE syringe filter.
  • Aliquoting: Dispense into single-use, amber vials or low-bind microtubes to avoid adsorption and repeated freeze–thaw. Typical aliquot volumes: 10–100 μL.
  • Freeze–thaw: Minimize cycles; repeated freeze–thaw can promote degradation or precipitation. Keep a working aliquot at 4 °C for same-day use; return unused portions to −20 °C promptly.
  • Aqueous dilution: Add DMSO stock to pre-warmed buffer with vigorous mixing to avoid local supersaturation. Verify absence of precipitation visually and, if critical, by light scattering or analytical HPLC.
  • Stability: Lot-specific stability data and retest dates are provided on the CoA/Spec Sheet. If long-term storage is required, consider −80 °C for DMSO solutions and evaluate stability empirically.

Note: For research use only; not for human or veterinary use.

Structure and Identity

Lazertinib is supplied as a research-use small molecule (Moligand series). Structural identifiers for this catalog item are limited in the Product Data; key registry numbers are provided below.

  • Product Name: Lazertinib (research use only)
  • CAS: 1903008-80-9
  • PubChem CID: 121269225
  • InChIKey (as listed in catalog entry): 324083 (note: appears truncated; consult CoA/SDS for the full identifier)
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

General structural description (literature, for context only):

  • Lazertinib is a third-generation EGFR kinase inhibitor scaffold that typically features an anilide core bearing an acrylamide Michael acceptor (for covalent engagement of a nucleophilic cysteine in the EGFR active site), along with heteroaromatic and halo/alkoxy substituents that tune potency and selectivity. The 2D structure can be described as a substituted anilide linked to an electrophilic acrylamide moiety and additional heteroaryl ring system(s), creating a flat, polyaromatic framework with one electrophilic side chain.

Notes:

  • Item-specific structural identifiers (full InChI, SMILES, exact formula and mass) should be taken from the item’s CoA/Spec Sheet to ensure traceability for analytical work.
Synthetic Utility

Lazertinib is supplied as a finished bioactive compound, not as a synthetic intermediate. It is generally not used as a reagent or synthon in preparative organic chemistry.

If derivatization is pursued for probe development (general considerations):

  • Covalent EGFR inhibitor scaffolds often contain an electrophilic acrylamide that is essential for activity; modifications to this warhead can abolish function. Non-warhead positions (e.g., peripheral aryl substituents or solubilizing side chains) are typical sites for installing tags (fluorophores, biotin) via amide coupling or click-ready handles introduced synthetically on a precursor.
  • Protecting-group strategies and chemoselectivity are critical to avoid Michael addition or degradation of the acrylamide under basic/nucleophilic conditions.

For most laboratories, the practical “utility” of this product lies in its role as a well-characterized screening compound rather than as a building block.

Target Specificity

Target specificity data (e.g., primary target, binding constants, selectivity panels) are not provided in the Product Data for this SKU.

  • Item-specific biological target information: Not specified for this item; refer to literature and to any assay data you may generate in-house.
  • For project planning, consult peer-reviewed studies on Lazertinib to understand typical target engagement profiles, but do not treat literature values as specifications for this catalog item.

Foire aux questions

What is the purity of this product?
This product is supplied at ≥98% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.
What is Moligand??
Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.
How should this product be stored?
Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 1903008-80-9, the molecular formula is C30H34N8O3, and the molecular weight is 554.64 g/mol. InChIKey RRMJMHOQSALEJJ-UHFFFAOYSA-N.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.